Milano, Italy
Milano, Italy

Time filter

Source Type

VIENNA, May 6, 2017 /PRNewswire/ -- Through intelligent and pioneering design, Elekta Unity (MR-linac) combines the best of both worlds to create a new paradigm for cancer care and provide extraordinary potential for 'hard to treat' cancers Today at the 36th ESTRO (European...

VIENNA, May 6, 2017 /PRNewswire/ -- Through intelligent and pioneering design, Elekta Unity (MR-linac) combines the best of both worlds to create a new paradigm for cancer care and provide extraordinary potential for 'hard to treat' cancers Today at the 36th ESTRO (European...

VIENA, May 6, 2017 /PRNewswire/ -- A través de un diseño inteligente y pionero, Elekta Unity (MR-linac) combina lo mejor de ambos mundos para crear un nuevo paradigma en el cuidado del cáncer y ofrecer un extraordinario potencial para tumores difíciles de tratar.     Hoy, en el tri...

WIEN, May 6, 2017 /PRNewswire/ -- Med en intelligent och banbrytande design kombinerar Elekta Unity (MR-linac) det bästa av två världar och skapar helt nya möjligheter för svårbehandlade tumörer.  I dag på den 36:e ESTRO-konferensen (European Society for Radiotherapy &...

News Article | May 6, 2017

WIEN, May 6, 2017 /PRNewswire/ -- Elekta Unity (MR-linac) vereint durch intelligentes und richtungsweisendes Design das Beste aus zwei Welten um ein neues Paradigma in der Krebsbehandlung zu schaffen und ein außergewöhnliches Potenzial für schwer zu behandelnde Krebsarten zu bieten  ...

Through intelligent and pioneering design, Elekta Unity (MR-linac) combines the best of both worlds to create a new paradigm for cancer care and provide extraordinary potential for 'hard to treat' cancers Today at the 36th ESTRO (European Society for Radiotherapy & Oncology) meeting, Elekta (EKTA-B.ST) introduced Elekta Unity, the only magnetic resonance radiation therapy (MR/RT) system that integrates a premium diagnostic quality (1.5 Tesla) MRI scanner with an advanced linear accelerator and intelligent software. Elekta Unity is expected to deliver precisely-targeted radiation doses while simultaneously capturing the highest-quality MR images, which will allow clinicians to visualize tumors at any time and adapt the treatment accordingly. Members of the Elekta MR-linac Consortium will be at ESTRO 36 to discuss expected clinical applications for the system. To view the Multimedia News Release, please click: In addition to enabling greater precision in radiation therapy dosing, Elekta Unity will feature several new patient-centric attributes designed to enhance patient comfort during treatment. These features include a compact, wide bore (70cm) MRI, soft tabletop, non-glare room lighting and a table that has a low load height to facilitate ease of patient entry and exit. Elekta Unity is expected to transform the treatment of cancer in several critical ways: "We started the development of an integrated MR-linac system 18 years ago; the presentation of the clinical system is a huge milestone," says Jan Lagendijk, PhD, Professor and Head Radiation Oncology, Department of Radiotherapy / Centre for Image Sciences, University Medical Centre Utrecht, and conceptual architect and inventor of the MR-linac system. "This system will enable tumor dose escalation and extreme normal tissue sparing, it will also enable shorter and more effective treatment regimens, while its ability to perform functional imaging has the potential to perform better dose painting and tumor response assessment." In October 2012, Elekta established a global consortium of partnering institutions to merge precision radiation delivery with MR imaging - from MR technology partner, Philips - in a single system. In addition to assuming responsibility for the core research and development and engineering activities, the consortium has generated the clinical and workflow protocols that will maximize the new system's therapeutic efficacy and ensure seamless integration into existing radiation oncology department procedures. "Elekta Unity is a technical tour de force through which we have overcome the longstanding limitations of operating a radiation delivery system within the high magnetic field of a diagnostic-quality MR imaging system," says Dr. Richard Hausmann, Elekta's President and CEO. "We are pleased to present Elekta Unity to the global oncology community here at ESTRO 36 and recognize this milestone as a testament to the expertise and perseverance of the members of the MR-linac Consortium. Elekta is grateful to all of our partners for their dedication to improving patient care and steadfast commitment to making Elekta Unity a reality." The Elekta Unity is not yet available for general sales in European markets with planned CE Mark for later 2017. Planned commercial availability worldwide to follow the CE Mark issuance. For more information, visit Elekta booth 3000 at ESTRO 36 or Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. For further information, please contact: Gert van Santen, Group Vice President Corporate Communications, Elekta AB Tel: +31-653-561-242, e-mail: Time zone: CET: Central European Time Raven Canzeri, Global Public Relations Manager, Elekta Tel: +1-770-670-2524, e-mail: Time zone: ET: Eastern Time

PubMed | The Ottawa Hospital Cancer Ctr and Elekta
Type: Journal Article | Journal: Medical physics | Year: 2017

To standardize the tube calibration for Elekta XVI cone beam CT (CBCT) systems in order to provide a meaningful estimate of the daily imaging dose and reduce the variation between units in a large centre with multiple treatment units.Initial measurements of the output from the CBCT systems were made using a Farmer chamber and standard CTDI phantom. The correlation between the measured CTDI and the tube current was confirmed using an Unfors Xi detector which was then used to perform a tube current calibration on each unit.Initial measurements showed measured tube current variations of up to 25% between units for scans with the same image settings. In order to reasonably estimate the imaging dose, a systematic approach to x-ray generator calibration was adopted to ensure that the imaging dose was consistent across all units at the centre and was adopted as part of the routine quality assurance program. Subsequent measurements show that the variation in measured dose across nine units is on the order of 5%.Increasingly, patients receiving radiation therapy have extended life expectancies and therefore the cumulative dose from daily imaging should not be ignored. In theory, an estimate of imaging dose can be made from the imaging parameters. However, measurements have shown that there are large differences in the x-ray generator calibration as installed at the clinic. Current protocols recommend routine checks of dose to ensure constancy. The present study suggests that in addition to constancy checks on a single machine, a tube current calibration should be performed on every unit to ensure agreement across multiple machines. This is crucial at a large centre with multiple units in order to provide physicians with a meaningful estimate of the daily imaging dose.

Ma D.J.,University of Washington | Michaletz-Lorenz M.,Elekta | Goddu S.M.,University of Washington | Grigsby P.W.,University of Washington | Grigsby P.W.,Washington University in St. Louis
International Journal of Radiation Oncology Biology Physics | Year: 2012

Purpose: To quantify the extent of interfractional vaginal cuff movement in patients receiving postoperative irradiation for cervical or endometrial cancer in the absence of bowel/bladder instruction. Methods and Materials: Eleven consecutive patients with cervical or endometrial cancer underwent placement of three gold seed fiducial markers in the vaginal cuff apex as part of standard of care before simulation. Patients subsequently underwent external irradiation and brachytherapy treatment based on institutional guidelines. Daily megavoltage CT imaging was performed during each external radiation treatment fraction. The daily positions of the vaginal apex fiducial markers were subsequently compared with the original position of the fiducial markers on the simulation CT. Composite dose-volume histograms were also created by summing daily target positions. Results: The average (± standard deviation) vaginal cuff movement throughout daily pelvic external radiotherapy when referenced to the simulation position was 16.2 ± 8.3 mm. The maximum vaginal cuff movement for any patient during treatment was 34.5 mm. In the axial plane the mean vaginal cuff movement was 12.9 ± 6.7 mm. The maximum vaginal cuff axial movement was 30.7 mm. In the craniocaudal axis the mean movement was 10.3 ± 7.6 mm, with a maximum movement of 27.0 mm. Probability of cuff excursion outside of the clinical target volume steadily dropped as margin size increased (53%, 26%, 4.2%, and 1.4% for 1.0, 1.5, 2.0, and 2.5 cm, respectively.) However, rectal and bladder doses steadily increased with larger margin sizes. Conclusions: The magnitude of vaginal cuff movement is highly patient specific and can impact target coverage in patients without bowel/bladder instructions at simulation. The use of vaginal cuff fiducials can help identify patients at risk for target volume excursion. Copyright © 2012 Elsevier Inc. Printed in the USA. All rights reserved.

Blueprint Software, an innovator and global leader in accelerating and de-risking large, complex IT projects, announced today that Elekta, a leading global human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders, selected Blueprint as its enterprise platform to manage software requirements as it expands its Agile practices. Elekta knew it needed to modernize its requirements practices by selecting a robust, enterprise scale requirements tool to: "We are very pleased to be supporting Elekta in the very important work that they do,” said Ruth Zive, Vice President of Marketing at Blueprint. "Elekta solutions can, quite literally, save lives, and we look forward to a strong partnership and long lasting relationship to that end." Elekta chose Blueprint as its enterprise requirements management platform because of their robust capabilities for traceability, reuse, and electronic signature, as well as its user friendly and intuitive UX. Elekta is already using the entire spectrum of Blueprint’s capabilities, from requirements definition and traceability to collaboration, use cases, workflows, for both product and customer level requirements. “As people start engaging with Blueprint, they get excited to use it. They definitely see it as superior to our old document-based approach,” said Jeff Hallett, Director, Gobal Process Engineering, Elekta. Elekta also plans to analyze (and measure where appropriate) improvement of productivity, quality, and collaboration with Blueprint in place as its enterprise requirements management solution. By retiring its manual spreadsheet and paper method and replacing it with Blueprint, Elekta will have a simpler, more maintainable electronic requirements management process. With a single shared requirements repository, teams can develop common product definitions and collaborate productively around a shared vision. For more information on how Blueprint is helping accelerate Agile adoption and solution delivery while managing regulatory constraints, please email info(at)blueprintsys(dot)com. Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radio-surgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives. Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,600 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: Blueprint provides industry-leading software solutions that help large organizations build better business applications. Our products – Blueprint, Storyteller and Blueprint Enterprise – resolve many of the time-consuming, costly, and error- prone functions that challenge IT organizations, thus ensuring that mission critical projects are completed successfully, on time and on budget. Organizations across the globe use Blueprint solutions to ensure regulatory compliance, speed transition to Agile, better align business and IT. Nearly half of all Fortune 100 companies choose Blueprint to de-risk and accelerate their software projects. For more information, please visit

Loading Elekta collaborators
Loading Elekta collaborators